CORRESPONDENCE
A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia Leukemia (2002) 16, 762-764. DOI: 10.1038/sj/leu/2402396 TO THE EDITOR Now that the relationship between the risk of relapse and persistence of high minimal residual disease (MRD) levels in marrow is clearly established in childhood acute lymphoblastic leukemia (ALL), an increasing number of treatment protocols will include MRD parameters for risk assessment. 1, 2 However, clinical use of MRD requires two conditions: quantitative MRD results must be available within the time required for a therapeutic decision, and the analysis should be reliable and applicable on a routine base to a large number of patients. We present here a simple and reliable method based on IGH, TCRD and TCRG detection, which enables rapid identification of patients with high MRD levels after completion of induction therapy. This assay relies on the identification of clonal rearrangements by their size only, using a fluorescent PCR with analysis of PCR products on an automated DNA sequencer. 3, 4 The PCR peak corresponding to the blast rearrangement is identified in remission samples by comparison of size to that obtained at diagnosis, thus eliminating the steps of sequencing and hybridization to clono-specific probes. We tested whether the more frequent combinations of TCRD, TCRG and IGH rearrangements were suitable for this type of technique and validated the assay by comparing MRD results obtained using this method with those obtained by hybridization to clono-specific probes.
PCR reactions permitting the detection of the most common combinations of IGH (FRIII-JH), TCRD (Vdelta2-Ddelta3) and TCRG (VgammaI-J1J2, VgammaI-JP1JP2, and Vgamma9-J1J2) genes were performed on each initial sample at presentation. The primers used were those described for diagnosis in Cavé et al 5 except for FRIII-JH primers. 6 One primer of each reaction was labeled with a fluorescent dye. PCR products were analyzed by capillary electrophoresis, detected by fluorescence, and visualized as peaks separated according to size on an Applied Biosystems ABI-PRISM 310 (ABI, Roissy, France) ( Figure 1 ). PCR amplification of TCR or IGH loci of polyclonal lymphocytes yielded products whose size is heterogenous, reflecting the diversity of the N-region. Size separation evidenced this heterogeneity and showed a Gaussian-like distribution of PCR products according to their size. On the other hand, electrophoresis of amplification products obtained from a monoclonal population of lymphoid cells having rearranged the locus of interest resulted in a single (or more) discrete peak whose size was highly clone-specific. This latter observation is consistent with the presence of a unique N-region in all lymphocytes. PCR products corresponding to the rearrangements were sized using the Genscan 672 program (ABI).
To determine whether the blast level was below or above a target value, we used a competitive PCR assay based on the co-amplification of an internal standard homologous to the target to be quantitated ( Figure 1 ). 5 Our purpose was not to give an accurate value for MRD but only to determine rapidly whether the blast level was below or above a target value that determines clinical management. Therefore, the standard curve was replaced by a single reference sample that mimicked a patient sample displaying a MRD level corresponding to the target value. The reference sample consisted of polyclonal mononucleated cells in which known amounts of patient's blasts and internal standard were added (Figure 1 as possible to the sample to test, a pool of MRD negative post-induction bone marrow was used as the source of polyclonal cells. This reference sample (1) ensures that the detection sensitivity of the marker is adequate in case of a negative detection in the tested sample, and (2) determines whether the level of MRD is above or below a given threshold in case of a positive detection in the tested sample.
The more frequent combinations of TCRD, TCRG and IGH rearrangements were all suitable for this type of analysis, but permitted to detect MRD with variable sensitivities ( Table 1 ). The sensitivity of the detection was mainly determined by the relative amount of PCR products amplified from the polyclonal marrow cells present in the samples (polyclonal background). The lowest background, and thus, the highest sensitivity for MRD detection, was observed for Vdelta2-Ddelta3 rearrangements, with 85% of alleles being still unambiguously detected at a 10 −3 dilution (Table 1) . On the other hand, the higher background was observed for the VgammaI-J1J2 rearrangements and 28% of the alleles remained undetected at a 5 × 10 −3 dilution (Table 1) . In this latter case, a better sensivity could be achieved by using distinct sets of V or J primers instead of consensus ones. For a given rearrangement, the detection sensitivity also varied with the size of the marker. Markers whose size was within the Gaussianlike distribution of polyclonal rearrangements were more difficult to detect than those whose size was borderline or outside the distribution. The presence of bi-allelic rearrangements did not affect the detection sensitivity. Altogether, these variations make it very important to check the detection sensitivity for each patient, using a reference sample whose composition is as close as possible to the sample to test. Moreover, it emphasizes the need for quantitation, since a positive result can correspond to either a 10 −4 or a 10 −2 MRD level, which have very different clinical meanings.
Assuming that at least two clonal rearrangements were found in more than 75% of ALL, a 5 × 10 −3 sensitivity for MRD detection can be obtained for virtually all patients and a 10 −3 sensitivity with at least one marker for up to 80% of patients. To increase the percentage of patients for whom two sensitive markers are obtained, a possibility is to study additional markers. For instance, in our laboratory, FRI-JH, Vdelta1-Jdelta1, and TCRG rearrangements involving Vgamma10 and Vgamma11 segments are studied in patients with no or only one marker. These markers are convenient for competitive PCR as well (data not shown). Other markers such as TCRB or the IGK gene deletions can also be studied. 7 The data presented here were obtained for post-induction samples. Average sensitivity was lower when studying off-therapy samples. Post-induction samples mostly contain cells from the erythroid and myeloid lineages and very few polyclonal lymphoid cells. Thus, detection is always more sensitive when blasts are diluted in post-induction marrow cells than when they are diluted in an equivalent number of normal marrow cells. For this reason, reference samples were done using a pool of MRD negative post-induction sample. When sampled at equivalent stages of marrow recovery, post-induction samples usually have a very similar cellular composition. However, to correct for minor variations, sensitivity can be more accurately assessed by using the remission sample itself as a source of polyclonal cells in the reference sample.
The reproducibility of the assay was good, with standard deviations below 15% when the internal standard was correctly chosen (Table  1 ). This rate of reproducibility is better than that obtained using clonospecific probes. 1 The correlation of MRD results obtained using fluorescent detection with those obtained using clono-specific hybridization was tested by reanalyzing 129 samples which had been previously studied by clono-specific probe hybridization.
1 Samples found to be negative using clono-specific probe detection (n = 50) were never found to be positive by fluorescent-PCR, which corresponds to 100% specificity
Figure 1
Competitive PCR amplification for MRD semi-quantitation using VgammaI-J1J2, FRIII-JH, and Vdelta2-Ddelta3 markers. Each series of PCR included (1) a 'test tube' containing 10 5 mononucleated cells of the remission sample to test, coamplified with 10 3 cells of internal standard, (2) a 'reference tube' containing 10 5 polyclonal mononuclear cells (from a pool of MRD negative samples obtained at remission), coamplified with 10 3 blasts of the patient studied and 10 3 cells of internal standard, and (3) a negative control on water. The internal standard consisted of a plasmid containing the sequence of a TCR or IGH rearrangement involving the same genomic segments as the patient's blasts, but with an N region of different length. After electrophoretic separation, PCR product peaks corresponding to the rearrangements of the patient and the standard were sized and quantitated. MRD was considered positive when the height of the peak of the patient's rearrangement was at least twice that of surrounding peaks amplified from the polyclonal cells. The height ratio of PCR peaks corresponding to patient's blasts to internal standard was measured in the 'test tube' (R Test ) and in the 'reference tube' (R Ref The ratio of unambiguously detected alleles to the total number of alleles tested is given for each dilution. a Many IGH rearrangements were only present in minor sub-clones, as assessed by the number of rearrangements (Ͼ2). Thus, the sensitivity was only considered for the major peak in each patient. b A different polyclonal marrow sample was used for each experiment. The high standard deviation observed for VgammaI-J1J2 is related to the fact that one rearrangement was within the size range of polyclonal rearrangements (and thus, its detection was influenced by the polyclonal sample composition which varied for each experiment), while the second rearrangement was outside the size range of polyclonal rearrangements.
of the assay. As expected given its lower sensitivity, fluorescent PCR failed to detect low-level MRD and permitted the detection of only 62% of the MRD-positive samples (52% of the samples studied using VgammaI-J1J2 rearrangement vs 67% for the rest of the markers, in accordance with the sensitivity data reported above). However, fluorescent detection gave positive MRD results for all samples displaying Leukemia more than 5 × 10 −3 residual blasts (n = 27), and in 22 of the 52 samples (42%) displaying MRD levels ranging from 10 −5 to 5 × 10 . Quantitative results were perfectly correlated to those obtained using clonospecific probes in all but two samples where the discrepancy is very likely due to deterioration of the samples over years. Results were similar when using a 5 × 10 −3 threshold and lower thresholds can of course be used in the same way, provided that the sensitivity is sufficient.
This technique has been successfully exported to several laboratories and has now been currently used for routine MRD detection in more than 500 patients. The rapid recognition of patients with a very bad prognosis is a major goal, because these patients display a very high risk of early relapse and alternative therapeutics have probably to be applied as soon as possible to be efficient. So far, the technique has enabled results to be known within 2 to 15 days of sample reception in virtually all patients displaying a TCR or IGH rearrangement, giving evidence of its feasibility. In view of the importance of methotrexate (MTX) therapy in the treatment of childhood ALL particularly during the consolidation and maintenance phases of treatment, identifying parameters associated with MTX sensitivity and resistance have direct relevance to the treatment of patients with ALL. Pharmacologic and biologic parameters which correlate with clinical MTX sensitivity and resistance in the treatment of ALL include: (1) altered intracellular MTX transport via the reduced folate carrier (RFC); (2) generation of long-chain MTXpolyglutamates catalyzed by folypolyglutamate synthase (FPGS); (3) levels of dihydrofolate reductase (DHFR), the primary target of MTX inhibition; and (4) the relationship of MTX sensitivity and leukemia cytogenetics including hyperdiploidy. [1] [2] [3] [4] [5] [6] It is conceivable that additional factors may also be determinants of MTX response.
The main mechanism of action of MTX as an anti-folate agent, results in the depletion of metabolically active pools of tetrahydrofolate cofactors with a suppression of folate-dependent synthesis of DNA, RNA and protein and thus, it is conceivable that alterations in reduced folate pools may lead to altered MTX sensitivity. Recently, polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR) (gene localized to 1p36.3), an enzyme which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the main circulating form of reduce folates, have been identified. Reduced activity of the MTHFR C677T allele (with the resultant substitution of valine for alanine), in both the heterozygous and homozygous state has been linked to hyperhomocysteinemia due to folate pool imbalances.
